维奈克拉长疗程治疗急性髓系白血病患者的疗效及安全性分析

Analysis of the efficacy and safety of a long course of venetoclax in the treatment of patients with acute myeloid leukemia

目的探讨维奈克拉联合方案长疗程治疗急性髓系白血病(acute myeloid leukemia,AML)患者的疗效和安全性,以指导更加个体化的临床应用。方法回顾性分析2021年1月至2023年7月于我院接受维奈克拉联合方案长疗程(≥6个周期)治疗的AML患者的病历资料,统计患者的复合完全缓解率、无进展生存期、总生存期以及不良反应发生情况。结果共纳入27例患者,中位随访时间为15(9.2~17.9)个月,维奈克拉联合治疗的中位周期数为8(6~28)个周期。在结束2个周期治疗后24例患者可评估疗效,复合完全缓解率为91.67%,部分缓解率为4.17%。所有患者首次获得复合完全缓解率的中位周期为1(1~2)个周期,随访期内55.56%的患者获得持续缓解。17例患者有微小残留病结果,微小残留病转阴率为58.82%。33.33%的患者微小残留病持续阴性,获得了持久而深度的缓解。27例患者中6例(22.22%)出现疾病进展。中位无进展生存期及总生存期均未达到,1年总生存率为84.21%。安全性分析以血液学不良反应最常见,其次为消化道症状、电解质紊乱、肺部感染、肝功异常等。结论维奈克拉长疗程治疗AML具有良好的有效性及安全性,部分患者可达深度而持久的缓解,维奈克拉可作为AML患者巩固及维持治疗的选择。

Objective To investigate the efficacy and safety of a long course of the venetoclax combination regimen in the treatment of patients with acute myeloid leukemia(AML),in order to guide a more individualized clinical application.Methods The medical records of AML patients who received a long course of treatment(≥6 cycles)with the combination regimen of venetoclax from January 2021 to July 2023 were retrospectively analyzed for the composite complete remission(cCR),progression-free survival(PFS),overall survival(OS),and the occurrence of adverse events.Results A total of 27 patients were included with a median follow-up of 15(9.2-17.9)months and a median number of cycles of VEN combination therapy of 8(6-28)cycles.After 2 cycles of treatment,24 patients were evaluated for efficacy,with a cCR of 91.67%and a partial remission of 4.17%.The median number of cycles to first cCR for all patients was 1(1-2)cycles,and 55.56%of patients achieved sustained remission.Seventeen patients had minimal residual disease(MRD)results,with a negative conversion rate of 58.82%for MRD.33.33%of patients with sustained negative MRD achieved a durable and deep remission.Among the 27 patients,6 patients(22.22%)had disease progression.The median PFS and OS were not achieved,with a 1-year OS rate of 84.21%.Safety analysis showed that hematologic adverse events were the most common,followed by gastrointestinal symptoms,electrolyte disorders,pulmonary infections,and liver function abnormalities.Conclusion A long course of venetoclax for AML has good efficacy and safety,and some patients can achieve deep and durable remission.Venetoclax can be used as an option for AML patients to consolidate their maintenance therapy.